Home › Gastrointestinal Stromal Tumors › Massachusetts
Gastrointestinal Stromal Tumors clinical trials in Massachusetts
9 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07218926KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07406633A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- University of Massachusetts Worcester, Worcester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT05957367Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699PH 2 Pemigatinib in SDH-deficient GIST
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07434843A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06630234A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Massachusetts General Hospital, Boston
- Harvard University, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06655246From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.